Study Comparing Izalontamab Brengitecan with Standard Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer After EGFR TKI Therapy Failure

Inclusion Criteria

• Have non-squamous non-small cell lung cancer (NSCLC) that cannot be treated with the intent to cure.
• Have a confirmed EGFR mutation, specifically exon 19 deletion or L858R mutation.
• The cancer must have progressed after treatment with a third-generation EGFR-TKI therapy, such as osimertinib, furmonertinib, or lazertinib, either alone or in combination with other treatments.
• Be eligible to receive a chemotherapy regimen that includes a platinum-based drug (cisplatin or carboplatin) combined with pemetrexed.

Exclusion Criteria

• Have inadequate organ function or low bone marrow reserves.
• Have cancer that has spread to the membranes surrounding the brain or spinal cord, or have spinal cord compression.
• Have poorly controlled medical conditions affecting the whole body.
• Other specific criteria as defined by the study protocol.